PD-1 × IL-2α-Bias: From Mechanistic Design to Durable Clinical Benefit
Immune checkpoint inhibitors have transformed cancer immunotherapy by restoring antitumor T-cell activity through blockade of the PD-1/PD-L1 axis. However, PD-1 inhibition alone does not always overcome the functional limitations of exhausted T cells, particularly in tumors with an immunosuppressive microenvironment or acquired resistance to immune checkpoint therapy.
This has driven growing interest in cytokine-based strategies that can simultaneously reinvigorate exhausted T cells and enhance their expansion and survival.
Among these approaches, PD-1 × IL-2 fusion proteins have emerged as a particularly interesting strategy. By combining PD-1-directed targeting with engineered IL-2 signaling, these molecules are designed to concentrate cytokine activity on PD-1-positive tumor-reactive T cells while reducing systemic IL-2 exposure.
The key challenge, however, lies not simply in combining PD-1 blockade with IL-2, but in determining how IL-2 receptor signaling should be engineered.
2026-08-26
